<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00282659</url>
  </required_header>
  <id_info>
    <org_study_id>WHIT001799HI</org_study_id>
    <nct_id>NCT00282659</nct_id>
  </id_info>
  <brief_title>The Use of Magnesium to Improve Blood Pressure, Cholesterol, and Glucose Control</brief_title>
  <official_title>The Use of Magnesium to Improve Hemodynamics, Cholesterol, and Glucose Control: A Substudy of AdMag</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hartford Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hartford Hospital</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if magnesium can improve blood pressure,&#xD;
      cholesterol, and blood sugar control in patients with implantable cardioverter defibrillators&#xD;
      (ICDs).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Magnesium is the second most abundant intracellular cation and plays a vital role in many&#xD;
      physiologic processes. It has been determined that patients with cardiovascular disease have&#xD;
      intracellular magnesium (Mgi) deficiencies. Among the ICD registries in Europe and the United&#xD;
      States 64% and 77% of patients also carry the diagnosis of CAD, respectively. Patients with&#xD;
      CAD have risk factors that lead to the development and or propagation of atherosclerosis.&#xD;
      Paramount among these risk factors are hypertension, dyslipidemia, and diabetes.&#xD;
&#xD;
      Comparison: Magnesium compared to placebo in patients with ICDs to evaluate the effect they&#xD;
      have on cholesterol, blood pressure, and blood glucose.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood pressure, cardiac output, systemic vascular resistance, thoracic fluid content, total cholesterol, low density lipoprotein, high density lipoprotein, triglycerides, and blood glucose</measure>
    <time_frame>at baseline, 3, and 6 months of follow-up</time_frame>
  </primary_outcome>
  <enrollment type="Actual">240</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Hypertension</condition>
  <condition>Dyslipidemia</condition>
  <condition>Diabetes</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>magnesium L-lactate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Newly implanted ICD or recent ICD shock (within 6 months)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to swallow&#xD;
&#xD;
          -  A non-cardiac disease with a survival prognosis of less than 12 months&#xD;
&#xD;
          -  Hypermagnesemia&#xD;
&#xD;
          -  Creatinine clearance less than 30mL/min&#xD;
&#xD;
          -  Lactic acidosis or systemic acidosis syndrome&#xD;
&#xD;
          -  Previous intolerance to magnesium L-lactate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles M White, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Connecticut School of Pharmacy, Hartford Hospital Division of Drug Information</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hartford Hospital</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06102-5037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>January 25, 2006</study_first_submitted>
  <study_first_submitted_qc>January 25, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2006</study_first_posted>
  <last_update_submitted>May 17, 2019</last_update_submitted>
  <last_update_submitted_qc>May 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hemodynamics</keyword>
  <keyword>Hypertension</keyword>
  <keyword>Dyslipidemia</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Implantable Cardioverter Defibrillator</keyword>
  <keyword>Blood Pressure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

